BioMarin to Host First Quarter 2014 Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET

SAN RAFAEL, Calif., April 16, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, May 1, at 5:00 p.m. ET to discuss first quarter 2014 financial results and provide a general business update. The conference call will be accessible via the internet from the company's website.

Dial-in Number  
U.S. / Canada Dial-in Number: (877) 303-6313 
International Dial-in Number: (631) 813-4731 
Conference ID: 30354748

Replay Dial-in Number: (855) 859-2056 
Replay International Dial-in Number: (404) 537-3406 
Conference ID: 30354748

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com . A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates. Approved products include VIMIZIM™ (elosulfase alfa) for MPS IVA; Naglazyme® (galsulfase) for MPS VI; Aldurazyme® (laronidase) for MPS I, a product which BioMarin developed through a 50/50 joint venture with Genzyme, a Sanofi Company; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany and Firdapse® (amifampridine), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include PEG PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 3 clinical development for the treatment of PKU, BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase 3 clinical development for the treatment of germline BRCA breast cancer, BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase 1/2 clinical development for the treatment of Pompe disease, BMN 111, a modified C-natriuretic peptide, which is currently in Phase 1 clinical development for the treatment of achondroplasia, BMN 190, a recombinant human tripeptidyl peptidase-1 (rhTPP1) for the treatment of late-infantile neuronal ceroid lipofuscinosis (CLN2), a form of Batten Disease, which is currently in Phase 1, BMN 270, an AAV-factor VIII vector, for the treatment of hemophilia A and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2), for the treatment of MPS IIIB.

For additional information, please visit www.BMRN.com .

Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 146

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 60

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
Strathcona and Greenfire Set Sights on Major Merger

Updated Category News Views 68

Strathcona's Bold Move for Greenfire: A Game Changer? Just this week, Strathcona Resources Ltd. decided to make a big splash in the oil sands space by proposing to acquire Greenfire Resources Ltd. This isn’t your run-of-the-mill grab—it's a strategic tango expected to shift billions and reshape what we know about Canada’s oil sands territory. Unpicking the Deal...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 272

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 354

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 414

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 646

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Cars.com Inducement Awards: New CPO Earns Stock Boost

Updated Category News Views 22

Revving Up With Incentives: A Strategic Move by Cars.com Ever seen a stock maneuver that feels more like a chess play than a plain deal? On November 5, 2026, Cars.com (NYSE: CARS) fired up quite a strategic engine. They handed out a heap of restricted stock units—373,345 to be precise—to Mausam Bhatt, freshly minted as their Chief Product Officer. This isn't just your...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 586

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading

Top 5 Most Recently Viewed Articles

Spring Health Launches Initiative for Mental Health Relief

Updated Category News Views 472

Spring Health's Commitment to Mental Health Support In response to the recent devastation from the wildfires, Spring Health has announced a significant initiative aimed at providing mental health resources to those in distress. The company has committed $500,000 to launch a new Wildfire Mental Health Support Program aimed at individuals and families impacted by these...

Continue Reading
Serina Therapeutics Showcases Innovations at Global Conference

Updated Category News Views 263

Serina Therapeutics Takes the Stage at Major Investment Event Serina Therapeutics, Inc., also known as Serina (NYSE American: SER), is set to make an impactful presentation at the H.C. Wainwright 27th Annual Global Investment Conference. This prestigious event unfolds in New York City, where Steve Ledger, the Chief Executive Officer of Serina, will take the spotlight at...

Continue Reading
Patrick Industries Faces Scrutiny Amid Merger Plans

Updated Category News Views 48

Cracks in the Merger Deal? Nobody likes it when a seemingly routine merger suddenly faces the magnifying glass of a class action attorney. But that's where we are with Patrick Industries (NASDAQ: PATK), folks. Juan Monteverde, the big hitter from Monteverde & Associates, is eyeing this one closely. This New York-based firm, perched in the legendary Empire State Building...

Continue Reading
Revolutionary Arab Human Pangenome: Advancing Genomic Equity

Updated Category News Views 124

Groundbreaking Achievement in Genomics PacBio, a renowned leader in sequencing technology, has made a substantial contribution to global genomics with the announcement of the first Arab human pangenome. This historic achievement is powered by their innovative HiFi long-read sequencing technology, showcasing the potential of genomic science to progress health equality...

Continue Reading
RCI Hospitality Secures Significant Legal Representation Ahead of Deadline

Updated Category News Views 226

Introduction to RCI Hospitality Holdings, Inc. RCI Hospitality Holdings, Inc. (NASDAQ: RICK) is known for its diverse portfolio in the hospitality sector. With establishments across the country, RCI focuses on providing entertainment and dining experiences through various brands. As an investor in RCI Hospitality, it’s essential to stay informed about recent legal...

Continue Reading